Tvardi Therapeutics, Inc. (NASDAQ:TVRD – Free Report) – Equities research analysts at HC Wainwright raised their Q3 2026 earnings per share estimates for shares of Tvardi Therapeutics in a research note issued to investors on Friday, August 14th. HC Wainwright analyst S. Nik now expects that the company will post earnings per share of ($0.61) for the quarter, up from their prior estimate of ($0.86). HC Wainwright has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for Tvardi Therapeutics’ current full-year earnings is ($2.32) per share. HC Wainwright also issued estimates for Tvardi Therapeutics’ Q4 2026 earnings at ($0.54) EPS, FY2026 earnings at ($2.56) EPS, FY2027 earnings at ($4.52) EPS and FY2028 earnings at ($6.24) EPS.
Tvardi Therapeutics (NASDAQ:TVRD – Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04).
Check Out Our Latest Stock Analysis on Tvardi Therapeutics
Tvardi Therapeutics Stock Performance
TVRD opened at $1.86 on Tuesday. Tvardi Therapeutics has a 1 year low of $1.50 and a 1 year high of $43.65. The company’s 50 day simple moving average is $2.47 and its 200 day simple moving average is $3.16. The stock has a market capitalization of $17.45 million, a PE ratio of -0.67 and a beta of 0.39.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. bought a new position in Tvardi Therapeutics in the second quarter worth about $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $43,000. Headlands Technologies LLC acquired a new position in Tvardi Therapeutics during the 2nd quarter valued at approximately $80,000. New York State Common Retirement Fund acquired a new stake in Tvardi Therapeutics in the second quarter worth $92,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Tvardi Therapeutics during the third quarter valued at $318,000. 44.66% of the stock is owned by institutional investors and hedge funds.
Tvardi Therapeutics Company Profile
Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.
Recommended Stories
- Five stocks we like better than Tvardi Therapeutics
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Tvardi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tvardi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
